Table 3. Univariate and multivariate analyses of survival by age, histology, and cancer stage.
| Variables | 5-year CSS | Univariate analysis | Multivariate analysis† | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Stage I | ||||||
| Age, years | ||||||
| 18–49 | 84.5% | Reference | Reference | |||
| 50–69 | 83.1% | 1.35 (0.73–2.51) | 0.3415 | 1.46 (0.77–2.79) | 0.2469 | |
| 70–79 | 69.0% | 2.46 (1.25–4.82) | 0.0091 | 1.74 (0.83–3.63) | 0.1418 | |
| ≥80 | 57.6% | 4.05 (2.15–7.62) | <0.0001 | 3.62 (1.72–7.63) | 0.0007 | |
| Histology | ||||||
| Squamous cell carcinoma | 80.9% | Reference | Reference | |||
| Adenocarcinoma | 83.6% | 0.91 (0.52–1.60) | 0.7442 | 1.07 (0.59–1.92) | 0.8337 | |
| Melanoma | 25.4% | 5.86 (3.75–9.14) | <0.0001 | 14.41 (7.30–28.42) | <0.0001 | |
| Sarcoma | 86.7% | 1.05 (0.33–3.33) | 0.9402 | 2.54 (0.74–8.78) | 0.1402 | |
| Other | 62.7% | 2.03 (0.97–4.23) | 0.0593 | 2.86 (1.32–6.21) | 0.0080 | |
| Stage II | ||||||
| Age, years | ||||||
| 18–49 | 74.1% | Reference | Reference | |||
| 50–69 | 75.0% | 1.18 (0.63–2.22) | 0.5986 | 0.95 (0.50–1.82) | 0.8746 | |
| 70–79 | 50.6% | 2.34 (1.22–4.48) | 0.0105 | 1.95 (1.95–0.98) | 0.0557 | |
| ≥80 | 35.9% | 3.92 (2.09–7.36) | <0.0001 | 2.70 (1.33–5.46) | 0.0058 | |
| Histology | ||||||
| Squamous cell carcinoma | 60.8% | Reference | Reference | |||
| Adenocarcinoma | 66.8% | 0.89 (0.58–1.35) | 0.5724 | 1.39 (0.89–2.19) | 0.1503 | |
| Melanoma‡ | 100.0% | 0 | 0.9933 | 0.00 | 0.9976 | |
| Sarcoma‡ | 100.0% | 0 | 0.9798 | 0.00 | 0.9933 | |
| Other | 61.8% | 0.86 (0.35–2.10) | 0.7373 | 1.52 (0.59–3.89) | 0.3871 | |
| Stage III | ||||||
| Age, years | ||||||
| 18–49 | 57.2% | Reference | Reference | |||
| 50–69 | 57.9% | 1.00 (0.58–1.73) | 0.9927 | 1.16 (0.65–2.07) | 0.6106 | |
| 70–79 | 55.6% | 1.29 (0.69–2.38) | 0.4265 | 1.35 (0.68–2.67) | 0.3892 | |
| ≥80 | 36.2% | 2.32 (1.27–4.21) | 0.0059 | 2.86 (1.43–5.72) | 0.0030 | |
| Histology | ||||||
| Squamous cell carcinoma | 55.0% | Reference | Reference | |||
| Adenocarcinoma | 60.3% | 0.90 (0.56–1.47) | 0.6769 | 1.07 (0.62–1.84) | 0.8082 | |
| Melanoma | 18.2% | 3.01 (1.56–5.79) | 0.001 | 3.54 (1.51–8.26) | 0.0035 | |
| Sarcoma | 0.0% | 3.77 (1.19–11.96) | 0.0242 | 1.91 (0.50–7.34) | 0.3453 | |
| Other | 47.6% | 0.94 (0.35–2.56) | 0.9052 | 0.82 (0.28–2.38) | 0.7168 | |
| Stage IV | ||||||
| Age, years | ||||||
| 18–49 | 31.0% | Reference | Reference | |||
| 50–69 | 26.9% | 0.98 (0.66–1.45) | 0.9101 | 1.03 (0.68–1.56) | 0.8746 | |
| 70–79 | 18.4% | 1.20 (0.77–1.86) | 0.4148 | 1.22 (0.75–1.98) | 0.4265 | |
| ≥80 | 6.3% | 2.04 (1.30–3.20) | 0.0018 | 2.47 (1.45–4.22) | 0.0009 | |
| Histology | ||||||
| Squamous cell carcinoma | 23.3% | Reference | Reference | |||
| Adenocarcinoma | 29.9% | 0.68 (0.47–0.97) | 0.0342 | 0.78 (0.53–1.14) | 0.2000 | |
| Melanoma | 0.0% | 1.59 (0.86–2.94) | 0.1356 | 2.02 (1.02–4.01) | 0.0449 | |
| Sarcoma | 17.1% | 1.76 (0.72–4.29) | 0.2155 | 2.53 (0.97–6.65) | 0.0589 | |
| Other | 12.9% | 1.10 (0.64–1.90) | 0.7319 | 1.36 (0.73–2.54) | 0.3301 | |
†, model adjusted for year of diagnosis, marital status, race, tumor size, grade, surgery, and radiation; ‡, this cohort included 1 stage II melanoma case and 1 stage II sarcoma case; both of these patients were still alive at last follow-up.